Physician profile
Cesar D Hidalgo
NPI 1477530806
$11,341.75
in general payments reported to CMS, 2019-2025
54 companies · $1,891 in 2025
The $1,891 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $976 · 2021: $1,709 · 2022: $2,062 · 2023: $1,711 · 2024: $2,061 · 2025: $1,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,646 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,646.18 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,742.86 | 2020-2025 | |
| Ucb, INC. | $856.99 | 2021-2025 | Rystiggo |
| Allergan, INC. | $636.79 | 2019-2022 | |
| Genzyme Corporation | $619.13 | 2019-2025 | |
| Argenx US, INC. | $519.43 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $469.91 | 2019-2024 | |
| Celgene Corporation | $447.72 | 2021-2025 | Zeposia |
| Neurelis, INC. | $407.22 | 2020-2025 | Valtoco |
| Lilly USA, LLC | $349.25 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Eisai INC. | $348.01 | 2019-2025 | |
| Amgen INC. | $313.99 | 2020-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $311.40 | 2019-2025 | Nuplazid |
| Biogen, INC. | $303.11 | 2020-2025 | Vumerity, Tysabri |
| Sk Life Science, INC. | $302.57 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $262.85 | 2021-2024 | Fasenra |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Hidalgo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.